CST Announces Pilot Study to Evaluate PhosphoScan™ Platform for Kinase Inhibitor Phosphoproteomic Profiling
News Aug 02, 2005
Cell Signaling Technology, Inc. (CST) has announced an agreement with Novartis under which a pilot study was performed using CST's PhosphoScan™ technology to identify phosphorylation sites and prospective biomarkers of protein kinase targets.
CST's PhosphoScan™ phospho-proteomics technology enables the determination of cellular kinase phospho-profiles (Phospho-Signatures™) and is based on patent-pending methodologies combining immunoaffinity purification and mass spectroscopy.
The PhosphoScan™ technology was described in the journal, Nature Biotechnology (Rush J. et al, Nat. Biotechnol. 23, 94-101 (2005)). The phospho-profiles discovered with PhosphoScan™ may enable biomarker assays for target validation and kinase inhibitor clinical development.
"Our PhosphoScan™ pilot with Novartis was a great opportunity to demonstrate the utility and value of cellular phospho-profiles and modulation of these by kinase inhibitors," said Christopher Bunker, CST's Director of Business Development.
"We are able to use PhosphoScan™ to deliver focused, in-depth Phospho-Signatures™ of disease cells and tissues and provide the basis for kinase biomarkers. CST superiority in antibody and immunoassay development is fully integrated with PhosphoScan™, and this can enable CST to translate PhosphoScan™ discoveries into validated biomarker assays."
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
SCRaMbLE Speeds Up Yeast EvolutionNews
Scientists have created a new way of speeding up the genome evolution of baker’s yeast Saccharomyces cerevisiae. This is to develop a synthetic yeast strain that can be transformed on demand, making it industrial applications such as the mass production of advanced medicines to treat illnesses such as malaria and tuberculosis (TB).READ MORE
Artificial Cellular Compartments BuiltNews
How to install new capabilities in cells without interfering with their metabolic processes? A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München have altered mammalian cells in such a way that they formed artificial compartments in which sequestered reactions could take place, allowing the detection of cells deep in the tissue and also their manipulation with magnetic fields.READ MORE